Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 337

recruiting
3 987
countries
28
conditions
2 109

4 235 trials match your criteria

Hepatocellular carcinoma

Not recruiting

Study of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Endometrial cancer+4

Not recruiting

Study on the Safety and Effectiveness of SKB264 and Pembrolizumab for Patients with Cervical, Urothelial, Ovarian, or Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Caffeine

Triple negative breast cancer

Not recruiting

Study on Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Early and Metastatic Triple Negative Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Factor IX deficiency

Not recruiting

Study on the Efficacy and Safety of Fidanacogene Elaparvovec Gene Therapy in Adult Males with Moderate to Severe Hemophilia B

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Fidanacogene Elaparvovec

Hepatocellular carcinoma

Not recruiting

Study of Pembrolizumab as Additional Treatment for Patients with Liver Cancer (Hepatocellular Carcinoma) After Surgery or Local Ablation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Haemophilia

Not recruiting

Study on Fitusiran for Preventing Bleeding in Males Aged 12 and Older with Severe Hemophilia A or B, with or without Inhibitors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Fitusiran

Colorectal cancer+5

Not recruiting

Study of Subcutaneous Nivolumab with or without Recombinant Human Hyaluronidase PH20 for Patients with Lung, Kidney, Melanoma, Liver, Colorectal, or Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Neoplasm

Not recruiting

Study on the Safety and Effectiveness of TNG462 for Patients with Advanced or Metastatic Solid Tumors with MTAP Deletion

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Midazolam

Breast cancer+2

Not recruiting

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib

Non-small cell lung cancer

Not recruiting

Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effectiveness and Safety of DMX-200 with Losartan in Adults with Focal Segmental Glomerulosclerosis

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil

Cardiovascular disorder

Not recruiting

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.